Navigation Links
A first -- lab creates cells used by brain to control muscle cells
Date:11/22/2011

could safely and ethically be tested on living humans. The technique could potentially be more effective than testing in mice and other animals currently used to screen promising drug candidates and to develop other medical treatments.

Such conventional animal testing is not only slow and expensive, but often leads to failures that might be overcome with better testing options. The limitations of conventional testing options have dramatically slowed the emergence of new drugs, Hickman said.

The successful UCF technique began with a collaborator, Brown University Professor Emeritus Herman Vandenburgh, who collected muscle stem cells via biopsy from adult volunteers. Stem cells are cells that can, under the right conditions, grow into specific forms. They can be found among normal cells in adults, as well as in developing fetuses.

Nadine Guo, a UCF research professor, conducted a series of experiments and found that numerous conditions had to come together just right to make the muscle and spinal cord cells "happy" enough to join and form working junctions. This meant exploring different concentrations of cells and various timescales, among other parameters, before hitting on the right conditions.

"Right now we rely a lot on animal systems for medical research but this is a pure human system," Guo said. "This work proved that, biologically, this is workable."

Besides being a key requirement for any complete human-on-a-chip model, such nerve-muscle junctions might themselves prove important research tools. These junctions play key roles in Amyotrophic lateral sclerosis, commonly known as Lou Gehrig's disease, in spinal cord injury, and in other debilitating or life threatening conditions. With further development, the team's techniques could be used to test new drugs or other treatments for these conditions even before more expansive chip-based models are developed.


'/>"/>
Contact: Barbara Abney
barb.abney@ucf.edu
407-823-5139
University of Central Florida
Source:Eurekalert  

Page: 1 2

Related medicine news :

1. C-Section Rate Drops for First Time in a Decade in U.S.
2. First MacLean Center Prize in Clinical Ethics awarded to Dartmouths John Wennberg
3. 9/11 First Responders May Face Greater Heart Risks
4. Loss of weight associated with chronic illness may soon have first treatment
5. First large-scale study of pain reveals risk factors
6. First proof of principle for treating rare bone disease
7. Report identifies community health centers as Americas first responders in fighting obesity
8. First results of Angiomax (bivalirudin) vs. heparin in transcatheter aortic valve interventions
9. Jefferson is first academic medical center to offer FDA-approved BRAF mutation for melanoma patients
10. If Hamlet give the first or second hit: The development of Burkitts lymphoma
11. UGA researchers develop first mouse model to study important aspect of Alzheimer’s
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
A first -- lab creates cells used by brain to control muscle cells
(Date:9/30/2014)... in 2003 to slow the spiraling costs of drugs ... patients has had no meaningful impact on cancer chemotherapy ... Journal of Clinical Oncology published online today. ... treat colorectal and lung cancers, and did not find ... following the implementation of the recent Medicare law in ...
(Date:9/30/2014)... York, NY (PRWEB) September 30, 2014 ... falling demand have hampered growth in the Bread ... diets have caused consumers to moderate their consumption ... consumer preferences for premium varieties shrunk the market ... products. Successful operators proactively responded by introducing more ...
(Date:9/30/2014)... Federally Qualified Health Centers (FQHCs) granted new patient ... higher rates than other primary care practices (non-FQHCs), ... to results of a new 10-state University of ... Care . , Using data from a previous ... the investigators found that FQHCs community health ...
(Date:9/30/2014)... of allergy-related sudden deaths in the U.S., according to ... conducted by researchers at Montefiore Medical Center ... Yeshiva University . The study, published online today in ... also found that the risk of fatal drug-induced allergic ... and that such deaths increased significantly in the U.S. ...
(Date:9/30/2014)... NV (PRWEB) September 30, 2014 ... Blue Star Nutraceuticals designed to help maximize lean, strong ... optimizes the body’s absorption of glucose has caught the ... , “The main purpose behind Glycodrive is to help ... lean muscle,” reports Michaels. “Carbs are essential in the ...
Breaking Medicine News(10 mins):Health News:Landmark Medicare law had little impact on reducing chemotherapy cost 2Health News:Bread Production in the US Industry Market Research Report from IBISWorld Has Been Updated 2Health News:Bread Production in the US Industry Market Research Report from IBISWorld Has Been Updated 3Health News:Medicaid and Uninsured patients obtain new patient appointments most easily at FQHCs 2Health News:Comprehensive Study of allergic deaths in US finds medications are main culprit 2Health News:Glycodrive Review Exposes Blue Star Nutraceutical’s Supplement for Leaner, Stronger Muscles 2
... BFRM ) today announced its financial results for the ... of fiscal,year 2008. Net sales were $18.6 million for the ... the quarter ended December 31, 2006,an increase of $6.8 million ... ended December 31, 2007 as compared to $2.7 million for ...
... Mass., Jan. 31 Millennium,Pharmaceuticals, Inc. (Nasdaq: ... presentation,at the 2008 Merrill Lynch Global Pharmaceutical, ... live and may be accessed by visiting ... http://www.millennium.com ., (Logo: http://www.newscom.com/cgi-bin/prnh/19991220/MLNMLOGO ...
... Jan. 31 In hopes of gaining a better,grasp ... focusing more on sales training tools and techniques to,provide ... reps,the first year of training and preparation is critical ... rep of approximately $10,500 in,the first year of employment, ...
... January 31, 2008 All candidates running for office in ... care system for the United States that is second to ... its annual report on The State of the Nations Health ... designed to gain candidate commitments to support a series of ...
... KENILWORTH, N.J., Jan. 31 Schering-Plough,Corporation (NYSE: ... antifungal agent NOXAFIL(R),(posaconazole) Oral Suspension received an ... invasive Aspergillus infections in certain,high- risk patients ... Guidelines of the Infectious Diseases Society of ...
... ovarian failure, researchers report , , THURSDAY, Jan. 31 (HealthDay ... that prompts early menopause and might account for some ... that,s known for suppressing tumor growth -- apparently also ... quickly. When researchers deleted the PTEN gene in mice, ...
Cached Medicine News:Health News:BioForm Announces Financial Results for Quarter Ended December 31, 2007, Second Quarter of Fiscal 2008 2Health News:BioForm Announces Financial Results for Quarter Ended December 31, 2007, Second Quarter of Fiscal 2008 3Health News:BioForm Announces Financial Results for Quarter Ended December 31, 2007, Second Quarter of Fiscal 2008 4Health News:BioForm Announces Financial Results for Quarter Ended December 31, 2007, Second Quarter of Fiscal 2008 5Health News:BioForm Announces Financial Results for Quarter Ended December 31, 2007, Second Quarter of Fiscal 2008 6Health News:BioForm Announces Financial Results for Quarter Ended December 31, 2007, Second Quarter of Fiscal 2008 7Health News:2008 Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference to Webcast Millennium Presentation 2Health News:Vital Training Tools Elevate New Pharmaceutical Sales Reps into Top Performers During Critical First Year 2Health News:Achieving a US health care system 'second to none' 2Health News:Achieving a US health care system 'second to none' 3Health News:Achieving a US health care system 'second to none' 4Health News:New IDSA Clinical Practice Guidelines Recommend NOXAFIL(R) (Posaconazole) for Antifungal Prophylaxis in Certain High-Risk Patients 2Health News:New IDSA Clinical Practice Guidelines Recommend NOXAFIL(R) (Posaconazole) for Antifungal Prophylaxis in Certain High-Risk Patients 3Health News:New IDSA Clinical Practice Guidelines Recommend NOXAFIL(R) (Posaconazole) for Antifungal Prophylaxis in Certain High-Risk Patients 4Health News:New IDSA Clinical Practice Guidelines Recommend NOXAFIL(R) (Posaconazole) for Antifungal Prophylaxis in Certain High-Risk Patients 5Health News:New IDSA Clinical Practice Guidelines Recommend NOXAFIL(R) (Posaconazole) for Antifungal Prophylaxis in Certain High-Risk Patients 6Health News:Study Spots Gene That Plays Role in Infertility 2
(Date:9/30/2014)...  Tasly Pharmaceuticals, Inc., the world,s leader in ... the launch of Deepure. Deepure is ... and women concerned with supporting their overall health ... while helping keep their health care cost down.  ... formulas, namely, ProHeart PLUS, ImmunoPower PLUS, and Pro-Memory ...
(Date:9/30/2014)... 2014 Aileron Therapeutics, Inc. - Product ... Markets Direct,s, ,Aileron Therapeutics, Inc. - Product Pipeline ... Aileron Therapeutics, Inc.,s pharmaceutical research and development focus. ... current therapeutic developmental pipeline of Aileron Therapeutics, Inc.,s, ... assessment by drug target, mechanism of action (MoA), ...
(Date:9/30/2014)... , September 30, 2014 ... research report the "Glycobiology/Glycomics Market by Product [Enzymes ... MALDI-TOF), Kits, and Reagents], Application (Immunology, Oncology) ... to 2019", published by MarketsandMarkets, provides a ... challenges, opportunities, current market trends, and strategies ...
Breaking Medicine Technology:Aileron Therapeutics, Inc. - Product Pipeline Review - 2014 2Aileron Therapeutics, Inc. - Product Pipeline Review - 2014 3Glycobiology / Glycomics Market Worth $928.11 Million by 2019 2Glycobiology / Glycomics Market Worth $928.11 Million by 2019 3Glycobiology / Glycomics Market Worth $928.11 Million by 2019 4
... Orally Dissolving Film StripBioAlliance to Resubmit Loramyc(R) NDA WOODCLIFF ... products division of a wholly owned subsidiary of Par ... provides an update on two of its pipeline products. ... 7, 2009, Strativa submitted a New Drug Application (NDA) ...
... April 8 Phase III data, published online this ... Metabolism , showed that arzoxifene, an investigational selective estrogen ... Company (NYSE: LLY ), significantly increased lumbar ... postmenopausal women with normal or low bone mass, versus ...
Cached Medicine Technology:Strativa Pharmaceuticals Provides Product Pipeline Update 2Strativa Pharmaceuticals Provides Product Pipeline Update 3Strativa Pharmaceuticals Provides Product Pipeline Update 4Newly Published Phase III Study Shows Arzoxifene Significantly Increased Bone Mineral Density 2Newly Published Phase III Study Shows Arzoxifene Significantly Increased Bone Mineral Density 3Newly Published Phase III Study Shows Arzoxifene Significantly Increased Bone Mineral Density 4
... to optimize the accuracy and precision of ... is widely recognized by customers throughout the ... over the years and now covers a ... including filter tips, certified pure tips, stepper ...
... Finntips have been designed to optimize the ... of our tip products is widely recognized ... range has been extended over the years ... standard and special tips including filter tips, ...
... racks of 96 tips, Sterilized Diamond- Tips ... Sterilized Diamond Tips are irradiated by gamma-rays ... with a certificate of sterilization, specifying the ... certified free of detectable Rnase, Dnase, DNA, ...
... of 96 tips, Sterilized Diamond- Tips are ... Diamond Tips are irradiated by gamma-rays for ... a certificate of sterilization, specifying the date ... free of detectable Rnase, Dnase, DNA, RNA, ...
Medicine Products: